Camrelizumab Plus Platinum-Based Chemotherapy for Patients With T3N2 NSCLC

🔗 Access full article via JAMA Oncology

This randomized clinical trial assesses the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy vs chemotherapy alone for patients with resectable stage IIIA